Venturefonde fravælger diagnostikfirmaer: Der er ikke mange succeser

Det er så svært at få succes med diagnostiske produkter, at flere venturefonde har fraprioriteret området som et investeringsemne. To af dem er danske Novo Seeds og Sunstone Capital.
Søren Møller, managing partner i Novo Seeds, mener, at diagnostikselskaber har en svær forretningsmodel at arbejde med. | Photo: Novo Nordisk Fonden
Søren Møller, managing partner i Novo Seeds, mener, at diagnostikselskaber har en svær forretningsmodel at arbejde med. | Photo: Novo Nordisk Fonden

Mens de færreste nok vil sige, at det er let at rejse penge inden for life science-branchen i det hele taget, så har diagnostikselskaber et særligt sæt udfordringer. Specielt i Danmark, hvor storinvestorerne ikke vil lege med.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now


Further reading